Call to Schedule Free Consultation at Over 45 Centers Worldwide!
MD, PhD, MBA
Dr. David Greene, MD, PhD, MBA, stands at the forefront of regenerative medicine and healthcare innovation, blending clinical expertise with entrepreneurial vision. As the founder and CEO of R3 Stem Cell and US Lead Network, Dr. Greene has dedicated his career to advancing patient care and empowering medical practices through advanced therapies and digital marketing excellence.
A residency and fellowship-trained orthopedic surgeon, Dr. Greene began his journey in medicine with a deep commitment to helping others. After years in clinical practice, he recognized the transformative potential of regenerative therapies and the urgent need for better patient access and education. This insight led him to establish R3 Stem Cell, now a global leader in non-surgical treatment options using stem cell and PRP therapy. Under his leadership, R3 Stem Cell has performed over 26,000 procedures across more than 45 international clinics, offering hope and healing to patients worldwide.
Dr. Greene’s entrepreneurial spirit didn’t stop at clinical innovation. He also founded US Lead Network, a healthcare internet marketing company that leverages artificial intelligence to help medical and dental practices grow their patient base efficiently and ethically. His two books on healthcare internet marketing have become essential reading for providers seeking to navigate the complexities of digital patient acquisition. Recognized as a Top 20 Expert Author by Ezines.com – ranking #15 out of over 470,000 authors and #1 in Pain Management – Dr. Greene’s thought leadership has shaped the way healthcare professionals connect with patients online.
A defining moment in Dr. Greene’s career was his decision to leave clinical practice and focus entirely on innovation and education. “I’ve never been a fan of just settling for the status quo. Innovation is a cornerstone of what makes America great,” he reflects. This philosophy has driven R3 Stem Cell’s mission to provide affordable, high-quality regenerative care and to demystify stem cell therapies through comprehensive training courses and educational content for both providers and patients.
Dr. Greene’s work has garnered international recognition, including a feature on the cover of Corporate Vision magazine, where his commitment to affordable, accessible regenerative therapies was spotlighted. His impact extends beyond business metrics – he is known for his compassionate approach, always prioritizing patient education and ethical practice.
Outside of his professional life, Dr. Greene is inspired by the words of Maya Angelou: “My mission in life is not merely to survive, but to thrive; and to do so with some passion, some compassion, some humor, and some style”. He brings this ethos to his daily work, fostering a culture of innovation, empathy, and continuous learning.
When he’s not leading global healthcare initiatives, Dr. Greene enjoys sharing insights on social media, connecting with colleagues, and pursuing personal interests that keep him grounded and inspired.
Dr. David Greene’s journey is a testament to the power of combining clinical skill, business acumen, and a heartfelt commitment to making a difference – one patient, one practice, and one innovation at a time.
All Posts
Stem cells are raw or undifferentiated cells with unique regeneration potential. The cells have the ability to differentiate into a range of different cells. They may serve as a repair system as they replace tissues and cells lost due to disease or injuries. Phoenix stem
Amniotic fluid and umbilical cord products both have many uses in regenerative medicine. These materials are known as “products of conception”, and come from tissues such as the amniotic fluid itself, the umbilical cord tissue, Wharton’s jelly, and the umbilical cord blood. These stem cells
Stem cell therapy has emerged as the most promising treatment to stop and reverse the effects of degenerative disorders, such as knee arthritis. Research publications worldwide attest its effectiveness in fast becoming a non-invasive substitute to surgical method and an alternative source of knee cartilage
In recent times, there has been a buzz about exosome therapy and its regenerative capabilities throughout the medical scene. Its similarities to stem cell and platelet-rich plasma therapy have made it a new cutting-edge treatment for addressing cellular damage, pain, and inflammation with no side
Regenerative medicine has taken the world by storm in recent years. The idea that there could potentially be a treatment that is more effective than surgery and prescription medication yet pose a very small risk is revolutionary. Initially, regenerative medicine became synonymous with stem cell
As we age we are more and more likely to feel aches, pains, creaks, and squeaks of our joints. Many accept this as part of the aging process, but this seemingly forgets the incredible burden of osteoarthritis (also referred to as wear and tear or
Hypothyroidism is a condition that affects the functioning of a patient’s thyroid gland. It can cause the thyroid gland to produce an inadequate amount of thyroid hormone, leading to a wide range of symptoms all over the body. Stem cell therapy is now being considered
R3 Stem Cell Mexico is now offering a complimentary PRP with each booked stem cell procedure. The platelet rich plasma therapy may be used for an extremity or soft tissue injection either alone or in conjunction with a stem cell therapy. As the most cost-effective provider of
R3 Stem Cell Mexico is now offering treatment with 100 billion exosomes for only $3950. The treatments are available in both of R3’s Mexico locations including Tijuana and Cancun. They have been a revolutionary treatment option for patients who have either failed conventional therapy, or
R3 Stem Cell announced today that the company has achieved IRB Approval for its regenerative study titled, “Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Cardiac, Renal and Pulmonary Conditions”. The company will be acquiring data for
